Avid Bioservices Inc (CDMO)

[biopharm]

Would San Diego based Ambit Biosicence have any business with PPHM?

Ambit Bioscience

Someone brought to my attention that PPHM's Tom Sklenar updated his profile as :

Tom Sklenar
Sr. Clinical Trial Manager at Ambit Biosciences
Greater San Diego Area - Biotechnology

Current
Ambit Biosciences,
Peregrine Pharmaceuticals


Sr. Clinical Trial Manager
Ambit Biosciences: January 2014 – Present (2 months)

Sr. Clinical Trial Manager
Peregrine Pharmaceuticals August 2011 – Present (2 years 7 months)

And for those that like to make BMY connections:

Mark Foletta, (ex Amylin before BMY deal in 2012) was appointed to the board of Ambit Biosciences in the same month (JAN 2014) that Tom Sklenar started his double employment (PPHM+Ambit)

Is this one of SK mentioned (in his RBC presentation) many collaborations. What would they collaborate on ? :)

For what it is worth and with many thanks to the provider of this information who can take credit if wanted. I respect full privacy on ALL information that is send to me by non-public means.

CP, it seems as if whatever Peregrine came close to in the past that somehow, in someway.... in some BMS way, that something happens. This time, Mark Foletta-ex BMS appears at an amazingly just the right time on the Ambit BOD to vote for a sale of the company. I'm beginning to wonder how all these lucky events happen to ex-BMS guys and many land at NEA.

Daiichi Sankyo to Buy Ambit Biosciences

Daiichi Sankyo Co. has agreed to buy Ambit Biosciences for about $315 million, pointing to the potential of Ambit's drug candidate quizartinib, which is in late-stage trials for the treatment of acute myeloid leukemia.
...
...
The company is developing quizartinib for other uses, as well, with testing in five other early- and mid-stage trials ongoing. Ambit is also testing other drugs for the treatment of cancer and inflammation.

http://www.wsj.com/articles/daiichi-sankyo-to-buy-ambit-biosciences-1411990495

--------------------------

Funny, they mention the sale was due to Quizartinib, but I'd say someone was more interested in the "other drugs for the treatment of cancer and inflammation" in combination with Bavituximab possibly that Tom Sklenar's profile showed that he was working with Ambit and Peregrine....

I don't know anymore, it just seems statistically significant, for like BMS to pop up everywhere, anytime Peregrine is around.